Navigation Links
Martek Announces Second Quarter 2008 Financial Results
Date:6/4/2008

Second Quarter Highlights: - Record revenues of $90.7 million, up 18% from the prior year's second

quarter - Earnings per share of $0.28, an increase of approximately 87% over last

year's second quarter - Operating cash flow of $23.6 million (Year-to-date operating cash flow of

$38.8 million) - Launch of eight new food and beverage and four new nutritional supplement

products containing life'sDHA(TM)

COLUMBIA, Md., June 4 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced its financial results for the second quarter of fiscal 2008. Revenues for the second quarter were $90.7 million, up 18% from $76.7 million in the second quarter of fiscal 2007. Net income was $9.2 million, or $0.28 per diluted share, for the second quarter of fiscal 2008 compared with $4.9 million, or $0.15 per diluted share, in last year's second quarter.

Commenting on the quarter, Chief Executive Officer Steve Dubin said, "Martek's strong second quarter results reflect the continued execution of the Company's business plan. Martek's core infant formula business grew, especially overseas, and solid revenue increases were seen in non-infant formula markets. Interest from food, beverage and supplements companies in our nutritional oils continues to grow which should lead to further expansion of our non-infant formula business. In addition, advancements continue in the development of both new applications for life'sDHA(TM) as well as new products to support Martek's long-term growth."

Second Quarter and Year-to-Date Revenue Summary

Product sales in the second quarter
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
10. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... a provider of DNA-based anti-counterfeiting technology and product authentication ... 12, 2014 to discuss its fiscal third quarter results. ... with the SEC by the end of the day ... Sciences, Inc. management will host a conference call beginning ...
(Date:8/1/2014)... AACC, a global scientific and medical professional organization dedicated ... brand identity today that reflects the organization,s commitment to ... and continue to do what they do best: provide ... they need. " The laboratory professionals ... in saving lives and making people healthier," said AACC ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:7/31/2014)... City, CA (PRWEB) July 31, 2014 ... as consumers, are increasingly searching for food alternatives ... and nutritional benefits. The food ingredient market has ... budding players such as Vital Force Technology (VFT). ... with more than 4,000 energetic patterns, all tested ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3AACC Debuts Refreshed Brand Identity 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2
... Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), an ... the three and nine months ended September 30, 2011 ... adoption of its SmartChip System. "During the ... strategy to address the rapidly changing needs of the ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
Cached Biology Technology:WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:8/1/2014)... Modern humans appear in the fossil record about 200,000 ... ago that making art and advanced tools became widespread. ... the journal Current Anthropology finds that human ... testosterone levels at around the same time that culture ... innovation, making art and rapid cultural exchange probably came ...
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... key component of phloem, the conductive tissue through which ... molecules. Elongated cylindrical cells are capped at one end ... sieve tubes which in turn form a network throughout ... very special cells which play an important role in ... known about their differentiation," says Professor Yk Helariutta from ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3Developmental regulation of important plant phloem components discovered 2
... indicating that more than 50% of all osteoporotic hip fractures ... and treatment of osteoporotic fractures has become a major health ... Osteoporosis (IOF WCO), to be held for the first time ... the region to attend the leading global congress devoted to ...
... new drug trabectedin with pegylated liposomal doxorubicin provides clinical ... new results presented at the 33rd Congress of the ... The combination, which importantly does not include a ... women whose cancer recurs at least 6 months after ...
... N.C. A newly discovered chemical pathway that helps ... 20 common beta-blockers, drugs that are prescribed to millions ... Researchers from Duke University Medical Center tested 20 beta ... and carvedilol -- could stimulate a pathway recently found ...
Cached Biology News:IOF World Congress on Osteoporosis in Bangkok to address Asian issues 2Promising new treatment option for women with recurrent ovarian cancer 22 beta blockers found to also protect heart tissue 2
... new HydroFlex platform provides excellent performance, ... of 96-well format applications, including washing ... arrays, and vacuum filtration-to-waste, such as ... on-line control features set new standards ...
... Obtain Clean and Accurate Results ... to dramatically increase the sensitivity and accuracy ... of homogeneous cell types and multi-cellular structures ... This unique approach to microdissection-developed in 1996 ...
...
... with 5.6" TFT color screen, without Camera ... digital camera with 8.0 mega pixel resolution. It ... small budget. View image from large 5.6" TFT ... It is suitable to capture image for fluorescent ...
Biology Products: